II 全球机构情报

每日:科技领域之外的AI机遇

前往官网原文 ↗
完整研报正文
完整中文译文

每日:科技领域之外的AI机遇

来自工作室

播客:信号而非噪音 | AI交易处于十字路口,在Apple或Spotify上(6分钟)视频:亚太区首要关注 | 当前牛市及需关注的风险(5分钟)视频:市场指南 | 为何投资者应重新审视欧洲(4分钟)

今日观点

对人工智能交易的重估以及杠杆头寸在压力下的平仓,导致费城半导体指数在过去六周内从峰值到谷底下跌了28.6%。尽管近几日市场情绪略有改善,但我们认为,人工智能增长故事的下一阶段需要的不仅仅是持有与人工智能支出相关的公司。

我们已强调倾向于对科技板块采取选择性、平衡的配置方式,但投资者也可以从主题角度考虑人工智能机遇。事实上,由于该技术正在改变企业和行业,我们看到各领域中帮助赋能、支持或大规模应用人工智能的机会。

电力制约凸显了满足日益增长需求所需的投资。在我们看来,电力供应是人工智能发展面临的最大制约因素之一,也是替代风险最小的领域之一。发电能力和电网接入面临较长的建设周期,而芯片(其生命周期较短)可能受到制造芯片所需设备的长周期影响。这支撑了我们对电力和资源主题的积极看法,该主题聚焦于电力基础设施和工业技术相关的机会,这两者都是人工智能价值链中开发人工智能和满足日益增长的电力需求的关键组成部分。

人工智能需求继续支撑半导体行业。随着超级规模企业提高近期资本支出承诺的指引,我们继续看到人工智能价值链中半导体和硬件领域的受益者。但我们认为关键在于选择性,而现在最大的机会在于半导体设备。我们预计供应瓶颈在半导体设备领域将最为突出,并预测未来三年收入年复合增长率约为30%。我们还认为代工厂提供了令人信服的风险回报,因为供应过剩风险仍然可控,估值合理,定价能力正在改善。与此同时,计算领域应继续受益于智能体人工智能的日益普及。

医疗保健是一个前景广阔的人工智能应用领域。我们长期认为,人工智能应用是长期创造大部分价值的战场,而在这些应用中,医疗支出是价格弹性最小的商品之一。因此,我们认为拥有专有数据资产的制药和生物技术公司提供了独特的机会。事实上,人工智能在医疗保健领域的领先进展已经十分显著:Lila最新的mRNA疗法表现出比传统技术高一倍的疗效,而Insilico Medicine的人工智能发现药物治疗特发性肺纤维化已进入III期临床试验。我们继续看好全球医疗保健行业,并认为该领域提供了由长寿这一结构性趋势支撑的机会。

因此,除了持有科技股且不对任何单一证券持观点外,我们认为投资者还可以通过扩大对工业、公用事业和医疗保健的配置来把握人工智能增长机遇。

完整英文原文

From the studio

Podcast: Signal over Noise | AI trade at a crossroads, on Apple or Spotify (6 mins)Video: Top of Mind in APAC | The current bull market and risks to watch (5 mins)Video: Market Playbook | Why investors should revisit Europe (4 mins)

Thought of the day

A reassessment of the AI trade and the unwinding of leveraged positions under pressure have led to a peak-to-trough decline of 28.6% in the Philadelphia Semiconductor Index over the past six weeks. While sentiment has improved slightly in recent days, we believe the next phase of the AI growth story requires more than just owning companies linked to AI spending.

We have highlighted our preference for a selective, balanced approach to tech exposure, but investors can also consider AI opportunities from a thematic angle. In fact, since the technology is transforming businesses and industries, we see opportunities across sectors that are helping enable, support, or apply AI at scale.

Power constraints underscore the investment required to meet rising demand. Access to power is one of the biggest constraints in AI development, and it is also one of the areas with the least substitution risk, in our view. Power generation capacity and grid connections face long lead times, and chips, which have shorter life cycles, can be affected by the long cycles required to make the equipment that produces the chips. This underpins our positive view on the Power and resources theme, which focuses on opportunities related to power infrastructure and industrial technology, both essential parts of the value chain for developing AI and satisfying rising electricity demand.

AI demand continues to support semis. With hyperscalers raising guidance for their near-term capital spending commitments, we continue to see beneficiaries in the semiconductor and hardware segment of the AI value chain. But we think selectivity is key, and we see the biggest opportunity now in semicap equipment. We expect supply bottlenecks to be the most prominent for semicap equipment, and forecast revenue will increase at an annual compound growth rate of roughly 30% over the next three years. We also believe foundries offer compelling risk-reward, as oversupply risks remain manageable, valuations are reasonable, and pricing power is improving. Compute, meanwhile, should continue to benefit from the rising adoption of agentic AI.

Health care is a promising AI application. We have long held the view that AI applications are the battleground where most value will be created over the long term, and among those applications, health spending is one of the most price-inelastic goods. We therefore believe pharma and biotech companies with proprietary data assets offer a unique opportunity. In fact, AI-led advances in the health care sector have been notable: Lila’s latest mRNA therapeutics delivered performance twice as effective as conventional technologies, while Insilico Medicine’s AI-discovered drug to treat idiopathic pulmonary fibrosis has entered Phase III clinical trials. We continue to favor health care globally, and believe the sector offers opportunities backed by the structural trend of Longevity.

So, in addition to holding tech stocks and without taking any single-security views, we believe investors can also position for AI growth by broadening their exposure to industrials, utilities, and health care.

预览 PDF
1 / 110%

正在载入文档……

AI 分析
由 AI 依据上文研报生成 · 非原文直译、非机构原话 · 重要判断请核对官网原文
关键论点
  • 费城半导体指数六周内峰值至谷底下跌28.6%,表明AI交易正在重新评估。
  • 电力限制是关键瓶颈,交付周期长且替代风险低。
  • 半导体设备因供应瓶颈成为最大机会。
  • 医疗保健凭借专有数据资产提供独特的AI应用机会。
  • 投资者应扩大对工业、公用事业和医疗保健的敞口。
风险
  • 杠杆头寸进一步平仓可能加剧科技股抛售。
  • 电力限制可能比预期持续更久,延迟AI基础设施建设。
  • AI应用采用可能慢于预期,影响医疗保健等行业。